Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development, with one having already been licensed, albeit with limited distribution. We investigated the immunogenicity and protective efficacy of a chimeric virus vaccine candidate based on the insect-specific flavivirus, Binjari virus (BinJV), displaying the structural prM/E proteins of DENV (BinJ/DENV2-prME). In this study, we immunized AG129 mice with BinJ/DENV2-prME via a needle-free, high-density microarray patch (HD-MAP) delivery system. Immunization with a single, 1 µg dose of BinJ/DENV2-prME delivered via the HD-MAPs resulted in enhanced kinetics of neutralizing antibody induction when compared to needle delivery and complete protection against mortality upon virus challenge in the AG129 DENV mouse model.

We have recently reported the development of a new chimeric virus system to produce flaviviral vaccine candidates using a newly discovered insect-specific flavivirus (ISF) named Binjari virus (BinJV)12. Exchange of the prM/E genes of BinJV with those of pathogenic flaviviruses results in chimeric virions that structurally mimic the pathogen and replicate to high titres in mosquito cell culture, but retain the insect-specific phenotype of the ISF, rendering them incapable of replicating in vertebrate cells12. The safety profile of these chimeric viruses, in addition to the authentic presentation of potent neutralizing antibody-eliciting quaternary epitopes, makes these chimeric viruses an excellent alternative vaccine candidate12. As such, the efficacy of the BinJV-based chimeras to protect against viral challenge in mouse models for Zika (ZIKV), West Nile (WNV) and yellow fever (YFV) viruses have already been established12–14. However, producing potent virus-neutralizing antibodies from vaccination with non-replicating vaccines can be challenging, and so we explored the use of the high-density microarray patch (HD-MAP) for vaccine delivery15–17.

The HD-MAP is a solid injection moulded 1 cm × 1 cm polymer high-density microprojection array containing 5000 projections of 250 µm in length onto which vaccine is dry-coated18. Using a spring-loaded applicator, the HD-MAP delivers the vaccine directly into the epidermal and upper dermal layers of the skin, which contain a high concentration of antigen-presenting cells (APCs)19. The dynamic application and delivery of vaccine antigen by the HD-MAP induces the co-localization of damage-associated molecular patterns and vaccine-related pathogen-associated molecular patterns. The co-localization of these signals with APCs are thought to be responsible for the enhanced immune responses regularly observed when vaccines are delivered via the HD-MAP20,21. Furthermore, the HD-MAP enables fractional dosing when compared to standard injection methods in mouse and rat models15,19.
Here we investigate the ability of HD-MAP delivery of the novel BinJ/DENV2-prME to induce a robust immune response and protect against virus challenge in a mouse model.

RESULTS
Vaccine production and quantification
The characterization of the BinJ/DENV2-prME chimera has been previously described\textsuperscript{12}. In that study, chimeric virus replication kinetics in mosquito cells, antigenic authenticity and inability to replicate in vertebrate cells were confirmed\textsuperscript{12}. In the current study, BinJ/DENV2-prME vaccine antigen (Fig. 1a) was prepared and purified via a potassium tartrate gradient, yielding a wide opalescent blue band (Fig. 1b). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis and total protein staining revealed a preparation comprising the DENV structural proteins, including the presence of prM, indicative of a heterogenous population of mature and immature particles (Fig. 1c). The presence of immature particles is typical for DENV cultures due to the relative inefficiency of the furin cleavage motif\textsuperscript{22}. Transmission electron microscopy (TEM) analysis confirmed these observations (Fig. 1d). Using comparative densitometry, the concentration of virus was determined to be 4.67 mg/mL. The purified chimeric virus material was used for all subsequent immunization studies.

Comparative immune responses to DENV2 VLP and BinJV/DENV2-prME in AG129 mice
As the BinJ/DENV2-prME chimera is unable to replicate in vertebrate cells, it may be viewed as similar to an inactivated whole virus vaccine or a virus-like particle (VLP)-like vaccine. So, to evaluate the BinJ/DENV2-prME vaccine candidate, a comparative study was performed in AG129 mice to assess the performance of the chimeric BinJ/DENV2-prME antigen alongside a commercially available recombinant VLP-based antigen comprising DENV prM/E produced transiently in HEK293 human cells\textsuperscript{23}. Female AG129 mice were vaccinated three times, 21 days apart, with 1 µg doses of either BinJ/DENV2-prME or the DENV2 VLP, delivered by intradermal (ID) and subcutaneous (SC) injection with and without the adjuvant Quil-A (QA) (Fig. 2a). Anti-DENV IgG responses were detected in all vaccinated mice after administering three doses, regardless of the antigen or route (Fig. 2c). When administered via SC, significant differences in the anti-DENV IgG response were observed between the adjuvanted BinJ/DENV2-prME and DENV2 VLP groups (Fig. 2b, \( p < 0.0001 \)) but not the unadjuvanted counterpart (Fig. 2b, \( p = 0.9033 \)). However, the opposite was discovered for the ID vaccinated groups with significantly higher IgG titres observed between BinJ/DENV2-prME and DENV2 VLP without QA (Fig. 2b, \( p < 0.0001 \)) but not the unadjuvanted counterparts (Fig. 2b, \( p = 0.1351 \)). To examine the virus-neutralizing potential of the induced IgG, plaque reduction neutralization tests (PRNTs) were also performed (Fig. 2c). Neutralizing antibodies were detected for all vaccinated groups, except for those that received the DENV2 VLP without the QA adjuvant, indicating that a 1 µg dose of DENV VLP is not sufficient to induce a detectable neutralizing antibody response. Significantly higher neutralizing antibody titres were observed for mice vaccinated with BinJ/DENV2-prME via either ID or SC routes when compared to those receiving the DENV2 VLP (Fig. 2c, \( p < 0.0001 \)). When BinJ/DENV2-prME was administered with the adjuvant QA, higher neutralizing antibody titres were induced via only the SC route (Fig. 2c, \( p < 0.0001 \)).

BinJ/DENV2-prME provides protection against DENV challenge
Given the induction of a potent virus-neutralizing antibody, we examined the capacity of BinJ/DENV2-prME to elicit protection from challenge with a mouse-adapted virus isolate, DENV2 D220. Ten days after the third vaccination, mice were challenged with the experimentally determined dose of \( 10^5 \) plaque forming units (pfu) mouse-adapted DENV2, D220. In addition to clinical scoring and weight loss (Supplementary Fig. 1), the kinetics of viremia and
non-structural 1 (NS1) secretion were also determined. Non-vaccinated control mice showed severe clinical signs (Supplementary Fig. 1) accompanied with a rapid increase in viral load and NS1 levels within the first 5 days, at which point the mice were culled based on disease morbidity scoring (Fig. 3a–c).

All groups vaccinated with adjuvant afforded complete protection, except for the DENV2 VLP + QA SC group, which resulted in 40% survival (Fig. 3d). The survival rate coincided with the morbidity scores of the DENV2 VLP + QA SC group peak at day 4 of the challenge period, when mice were culled (Supplementary Fig. 1b). Data obtained from day 3 post virus challenge showed significant reduction in viremia and NS1 levels in mice receiving unadjuvanted BinJ/DENV2-prME, except for the SC vaccinated mice, which had no significant differences in NS1 level compared to their VLP counterparts (Fig. 3j, k). Although there was no significant difference between peak viral load and NS1 levels (as assessed at 3 days post challenge) in mice receiving BinJ/DENV2-prME + QA via SC, significantly lower viral loads were observed for the ID vaccinated groups (Fig. 3j, k). Overall, delayed kinetics was observed for both these biomarkers in mice receiving BinJ/DENV2-prME + QA as compared to VLP groups (Fig. 3e, f, j, k).

Vaccine coating and delivery via HD-MAPs

To build on the success of ID vaccination with BinJ/DENV2-prME, we investigated the utility of the HD-MAP delivery platform to further enhance immune responses. To deliver a known quantity/
desired dose of vaccine, we performed coating and delivery optimization of BinJ/DENV2-prME by HD-MAP. HD-MAPS were coated with BinJ/DENV2-prME formulated with previously defined excipients, 0.75% methylcellulose and 0.75% trehalose. Uncoated (Fig. 4a) and coated HD-MAPS were imaged by scanning electron microscopy (SEM) to observe coating uniformity before (Fig. 4b) and after coating removal following HD-MAP application to the mouse flank (Fig. 4c). HD-MAP coating with the vaccine formulation revealed smooth and even distribution on the microprojections (Fig. 4b). Removal of vaccine was observed at the tip of the microprojections, confirming that the vaccine had been delivered into the mouse skin (Fig. 4c). To quantify the amount of delivered vaccine, a subtractive enzyme-linked immunosorbent assay (ELISA) was performed, measuring the
amount of vaccine remaining on the microprojections following HD-MAP application. The amount of vaccine delivered was calculated to be 1.1 µg per HD-MAP as shown in Fig. 4d. After successful coating and determination of delivered vaccine, we proceeded to evaluate HD-MAP delivery of BinJV/DENV2-prME in the AG129 dengue mouse model.

**Immune response following HD-MAP vaccination**

Following the successful demonstration of protection from non-adjuvanted needle-based ID immunization, we evaluated protective efficacy of BinJ/DENV2-prME delivered by the HD-MAP in a single- or two-dose regimen. AG129 mice were immunized with 1 µg BinJ/DENV2-prME via ID injection or HD-MAP receiving one or two doses 21 days apart (Fig. 5a). Mice given a single dose of vaccine were challenged with 10^5 pfu of D220 21 days post primary immunization, whereas those groups receiving a second dose were challenged 21 days after the second dose (Fig. 5a). Before each vaccination and virus challenge, blood samples were collected and the serum was analysed for virus-specific IgG and neutralizing antibody (Fig. 5a). Mice vaccinated via the HD-MAP had significantly higher anti-dengue
IgG titres after a single dose compared to the ID vaccinated mice (Fig. 5b, p = 0.0005). An increase in IgG levels was observed after the second dose for both ID and HD-MAP groups, with higher antibody titres induced in the HD-MAP-vaccinated group (Fig. 5b, p = 0.01). To confirm the anti-DENV IgG from vaccinated animals was functional, we next investigated the ability of these antibodies to neutralize wild-type dengue (DENV2 ET200). Neutralizing antibody titres reflected vaccine-specific IgG responses with mice vaccinated with a single dose via the HD-MAP having significantly higher neutralizing antibody titres as compared to those vaccinated via ID (Fig. 5c, p = 0.01)).

The HD-MAP deposits vaccines directly to the APCs in the skin and it is known that DENV entry to dendritic cells is mediated by DC-SIGN24. To investigate whether the enhanced immune responses to Bin/J/DENV2-prME were due to limited RNA replication or de novo translation, DC-SIGN-positive cell lines K-562 and A549 were selected for analysis along with control C6/36 cells. Infected cells at 6 and 24 h were stained for double-stranded RNA (dsRNA) and NS1 (BinJV-specific and pan-flavivirus). Wild-type DENV2 infection resulted in the detection of dsRNA and limited NS1 in all cell lines tested (Supplementary Fig. 2). As previously observed by Hobson et al.12, the chimeric Bin/J/DENV2-prME was able to establish infection in C6/36 cells with both dsRNA and NS1 production (Supplementary Fig. 2a). However, the detection of dsRNA and NS1 was absent from the mammalian cell lines when infected with Bin/J/DENV2-prME (Supplementary Fig. 2b, c).

**DENV challenge of HD-MAP-vaccinated AG129 mice**

To evaluate the protective efficacy of one- or two-dose vaccination with Bin/J/DENV2-prME delivered by the HD-MAP and ID injection, we challenged vaccinated mice with 10^5 pfu of D220. Mice were monitored for clinical scores (including animal weight, Supplementary Fig. 3), viremia, NS1 levels and survival for 10 days following challenge (Fig. 6). Control mice rapidly deteriorated, exhibiting disease symptoms (Supplementary Fig. 3), which were concomitant with rapidly increasing viral load and NS1 levels with all mice being culled on days 4 and 5 (Fig. 6a–c). Following two doses of Bin/J/DENV2-prME via HD-MAP or ID injection, viral load and NS1 levels were significantly reduced as compared to the control mice (Fig. 6b, c, g, h). This reduction in NS1 and free circulating virus coincided with minimal disease symptoms and

---

**Fig. 6** Survival, viremia and NS1 secretion following Bin/J/DENV2-prME immunization. a, d Survival rates of mice over 10 days post challenge. b, e Mean viremias were determined by plaque assay on Vero cells. Limit of detection was 50 pfu/mL. c, f Serum levels of NS1 were determined using quantitative capture ELISA. To demonstrate the significant differences between viremia and NS1 levels, data from day 3 post virus challenge were plotted. Each symbol represents a single mouse. Lines indicates mean antibody titres with bars showing ±SEM. ****p ≤ 0.0001, ***p ≤ 0.0003, **p ≤ 0.002, *p ≤ 0.03 assessed by one-way analysis of variance (ANOVA, α-level 0.05).
complete protection from virus challenge (Fig. 6a and Supplementary Fig. 2b).

Following the success of two-dose vaccination, we investigated the protective efficacy of a single-dose vaccination regimen. The control group showed the same magnitude and kinetics of viral load, NS1 levels and disease progression/survival as described above (Fig. 6d–f and Supplementary Fig. 2). The HD-MAP-immunized group showed minimal signs of disease on day 4 and 5 with 100% of mice surviving the viral challenge (Supplementary Fig. 2b and Fig. 6d, respectively). The ID vaccinated group showed similar morbidity scores throughout the monitoring period, although peaking higher on day 4 when compared to the HD-MAP group (Supplementary Fig. 2b). This difference reflects the partial protection of 62.5% observed in the ID vaccinated group (Fig. 6d). Infection biomarkers, viral load and NS1 levels were significantly reduced for both ID and HD-MAP groups when compared to the control group (Fig. 6b, c, g, h). Comparing the two delivery methods, mice receiving the vaccine via HD-MAPS had significantly lower viral load with free circulating virus not detected until day 3 post infection (Fig. 6b, g). In contrast, mice vaccinated by ID injection showed a rapid increase in viral load following infection resulting in partial protection.

**DISCUSSION**

The development and licensure of an effective dengue vaccine has been a priority for more than 50 years25. Here we describe the application of an ISF platform technology to the development of a Bin/J/DENV2 chimeric virus as a dengue vaccine candidate. We further showed that vaccinated mice induced potent neutralizing antibodies against DENV, and that by combining the Bin/J/DENV2-prME antigen with the HD-MAP vaccine delivery platform, complete protection from virus challenge of AG129 mice could be elicited using a single unadjuvanted dose of 1 µg of Bin/J/DENV2-prME.

Although the licensure of Dengvaxia in 2016 was a major step forward in dengue vaccine development, limitations around its use because of safety concerns has ensured that the development of alternative vaccine strategies has remained a priority26–28. The two most advanced vaccine candidates currently in phase III clinical trials are DENVax by Takeda Vaccines (live attenuated chimeric virus with DENV2 backbone) and TV003/TV005 by US National Institute of Health (live attenuated Δ30 viruses)29,30. Subunit vaccine approaches employing the DENV E protein have also been explored, with their safety profile providing some advantages over live attenuated vaccines15,31.

There is a growing body of evidence that antibodies targeting quaternary epitopes, such as the dimer interface of the E protein, are important for virus neutralization. Although VLPs and inactivated whole virus vaccines have shown promise, it has been previously found that these vaccine candidates are not structurally identical to their infectious flavivirus counterparts12–14. These differences have been suggested to be due to presentation of the E dimers on the surface of the VLPs or through the chemical inactivation process of the whole virus vaccines.12–14. However, the Bin/J chimeras are structurally and antigenically identical to their infectious flavivirus counterparts12–14. In addition, although DENV VLP vaccine candidate have been shown to require administration over multiple doses along with an adjuvant12–14, we show in this study that a single unadjuvanted dose of Bin/J/DENV2-prME can elicited solid protection in a mouse model.

Our group has previously shown that Bin/J/vertebrate-infecting flavivirus (VIF)-prME antigen are highly immunogenic in mice, using vaccine candidates displaying the prM/E for WNV, YFV and ZIKV12–14,34. Indeed, consistent with the Bin/J/DENV2-prME vaccine candidate examined here, the analogous chimeras for ZIKV and WNV afforded complete protection in their respective mouse models using a 1 µg dose and without the use of adjuvant. Although immunization via ID with adjuvanted Bin/J/DENV2-prME elicited potent IgG and neutralizing antibody titres, providing complete protection upon virus challenge, higher viral loads and NS1 levels were noted in this immunized group when compared to their unadjuvanted counterparts. By contrast, mice vaccinated via ID injections with Bin/J/DENV2-prME without adjuvant achieved complete protection, suggesting that the addition of QA may not be necessary.

Vaccine administration by the ID route targets the dermis and epithelium of the skin, a location rich in APCs, and elicits more enhanced immune responses than SC or intramuscular injection33. However, it is also technically challenging to successfully administer an ID injection and requires a trained personnel33. To overcome this limitation, there has been a growing interest in alternative vaccine delivery platforms such as microneedles/microarray patches, which have shown varying degrees of efficacy in mouse models15,34–36. Using HD-MAPS, our group has previously shown the induction of enhanced immune responses with significant dose sparing15–17,19. Taking advantage of the dose reduction potential of the HD-MAP, we evaluated the protective efficacy of delivering Bin/J/DENV2-prME to the skin via this approach. Our findings show that all mice receiving a single dose of Bin/J/DENV2-prME delivered by HD-MAP had significantly reduced levels of viremia and NS1 when compared to control mice following virus challenge, and were fully protected (Fig. 5). Although these results are promising, one of the limitations of our study is the focus on a single serotype of DENV. As such, no comment can be made to the short-term vs. long-term protective efficacy of antibodies produced by the vaccination. Likewise, further investigation with regards to cross-reactivity with the other DENV serotypes or flaviviruses is warranted.

This is the primary study to demonstrate the effective delivery of a novel chimeric virus vaccine candidate, Bin/J/DENV2-prME, by the HD-MAP. The targeted delivery of a single dose of the vaccine to the skin raised potent immune responses that afforded protection to DENV challenge in the AG129 mouse model. With the success of a single dose of Bin/J/DENV2-prME delivered by HD-MAP, the production and evaluation of the remaining three dengue serotypes are currently under investigation. In addition to the successful pre-clinical studies using these chimeras for WNV, YFV and ZIKV, the efficacy of constructs for other flaviviral diseases are also being explored. Coupled with targeted skin delivery, these chimeric viruses offer a promising new vaccine platform for the future development of a wide range of flavivirus vaccines.

**METHODS**

**Animal ethics**

Animal experiments were approved by the University of Queensland animal ethics committee (AEC No: SCMB/ALBN/150/16/NHMR) and were performed in accordance with National Health and Medical Research Council guidelines. Animals were housed under specific pathogen-free conditions in the University of Queensland Biological Resources animal housing facility at the Australian Institute for Bioengineering and Nanotechnology.

**Cell lines**

Vero cells (African green monkey kidney) were maintained in OPTI-MEM (Gibco) cell culture medium, containing 3% fetal bovine serum (FBS, Bovogen) at 37 °C with 5% CO2. Bovine (Bovogen) at 37 °C with 5% CO2. C6/36 (Gibco) medium, supplemented with 10% FBS, 15 mM HEPES (Gibco), 1% Glutamax (Gibco), 100 U/mL penicillin (Gibco) and 100 µg/mL streptomycin (Gibco) at 37 °C with 5% CO2.

Published in partnership with the Sealy Institute for Vaccine Sciences
Bin/J/DENV2-prME chimeric virus propagation and purification

The generation and production of Bin/J/VF-prME chimeras were previously described[12]. C6/36 cells at 80% confluency were infected with Bin/J/DENV2-prME at a multiplicity of infection (MOI) of 0.01. Supernatant was collected at days 3, 5 and 7 post infection. The virus culture supernatant was clarified by centrifugation at 3000 × g for 15 min at 4 °C, filtered through a 0.22 µm filter (Millipore) and stored at 4 °C until purification. After each collection, cells were replenished with fresh RPMI media containing 2% FBS. The Bin/J/DENV2-prME virions were precipitated via addition of polyethylene glycol 8000 (Sigma Aldrich) to a final concentration of 8% and slow stirring overnight at 4 °C. The virus was pelleted at 12,000 × g for 1 h at 4 °C, followed by ultracentrifugation through a sucrose cushion and potassium tartrate gradient as described by Warrillow et al.[17]. Purified virus was collected and buffer-exchanged into phosphate-buffered saline (PBS) using a 30 kDa Amicon filter (Millipore) and stored at 4 °C.

SDS-PAGE analysis of purified virus

Purified viruses were run on a 4–12% Bis-Tris gel to confirm production, purity and molecular weight of viral protein (Supplementary Fig. 4). Samples were prepared with 4× SDS buffer and boiled for 5 min before SDS-PAGE separation. Gels were run at 150 V for 1 h. Gels were stained with GelCode Blue Stain (Thermo Fisher) according to the manufacturer’s instructions. Quantification of viral protein was performed as mentioned by Vet et al.[15].

Negative-stain TEM

Bin/J/DENV2-prME particles were purified as described above. Purified virions were dried onto a freshly glow-discharged 200-mesh square carbon-coated copper grid (Proscitech). Grids were then stained with 2% uranyl acetate and imaged by TEM on a Hitachi HT 7700 at 100 kV.

HD-MAPS coating and application

HD-MAPS (1 cm², 5000 projections/cm² at 250 μM in length) were kindly provided by Vaxxas Pty Ltd, Brisbane, Australia. HD-MAPS were plasma treated with oxygen for 3 min at Australian National Fabrication Facility before vaccine coating. Coating solution made up for five HD-MAP consisted of 19.7 μL of 4% methylcellulose, 15.5 μL of 5% trehalose and 5.35 μL of 4.67 mg/mL purified Bin/J/DENV2-prME in low-salt buffer (20 mM Tris and 75 mM NaCl pH 7.4). The coating solution (21 μL) was added onto each patch and dry-coated on to the microprojections under a nitrogen jet directed using a 25G needle applicator.

Delivery efficiency

A subtractive DENV Envelope (E) protein ELISA was performed to determine the dose delivered to the flank by HD-MAPS. Briefly, 50 μL of DENV antibody humanized C816[13] in bicarbonate buffer (0.05 M carbonate–bicarbonate buffer pH 9.6, Sigma Aldrich) was coated on ELISA plates (Nunc Maxisorb, Thermo Fisher) overnight at 4 °C. Plates were blocked with blocking buffer (KPL, SeraCare) for 1 h at room temperature.

To generate a standard curve, 1 μg/mL of Bin/J/DENV2 was added and titrated via doubling dilutions across the plate. Remaining vaccines were eluted off coated, patched HD-MAPS and coated, unpatched HD-MAPS by pipetting blocking buffer onto all four corners and the middle of the HD-MAP five times. The eluted vaccines (50 μL/well) were then added to the ELISA plate and incubated at 37 °C for 1 h alongside the Bin/J/DENV2-prME standard curve. Plates were then washed 3x with PBS–0.05% Tween-20 (PBS-T). DENV antibody humanized S1314, conjugated with horse-radish peroxidase (HRP, Abcam) according to the manufacturer’s instructions, was added and incubated at 37 °C for 1 h. Plates were then washed 6x with PBS-T and 50 μL/well of Tetramethylbenzidine-w (TMBW, Biofx) was added. Relative absorbance was read at 450 nm on a plate reader. Dose delivered was determined by measuring the difference between the amount of vaccine recovered from coated HD-MAPS, pre and post application.

Scanning electron microscopy of HD-MAPS

HD-MAPS were imaged by SEM using a JEOL JCM-5000 Neoscope with samples tilted at a 45° angle. Imaging of the HD-MAPS was performed as previously described[15]. All images were taken at high resolution at 10 kV.

Immunofluorescence assays

Ninety-six-well black optical plates (Thermo Fisher) were treated with Poly-L-Lysine (Thermo Fisher) for 30 min at 37 °C. Plates were washed 2x with sterile PBS and left to dry overnight. A549 cells were seeded at 1 × 10⁴ cells/well and K-562 cells were seeded at 3 × 10⁵ cells/well overnight at 37 °C. C6/36 cells were seeded at 3 × 10⁶ cells/well overnight at 28 °C. Cells were infected with Bin/J/DENV2-prME or DENV2 E700 at an MOI of 1 or were mock infected and incubated at room temperature with rocking for 1 h. The virus inoculum was removed and cells were washed 3x with sterile PBS. Appropriate growth media for each cell line was added and incubated for 6 and 24 h post infection at 28 °C or 37 °C for the indicated mammalian and insect cell lines. Cells were fixed with 4% paraformaldehyde in PBS with 0.1% Triton X-100. Fixed plates were blocked in 1% bovine serum albumin (BSA)/PBS for 1 h at room temperature before adding 50 µL of mouse anti-3G1[18] (1 : 3), mouse/human anti-4G6[19] (1 : 10; 1 : 500), mouse anti-7G10[20] (1 : 5) or mouse anti-DC-SIGN (1 : 500) mAb diluted in 1% BSA/ PBS/0.1% Tween-20 to the respective wells. Plates were incubated for 1 h at 37 °C and then washed 4x with PBS-T. Fifty microdrops of secondary antibody Goat anti-mouse Alexa Fluor 488 or Goat anti-human Alexa Fluor 647 diluted 1 : 5000 were added into the respective wells and incubated at 37 °C for an hour. Plates were then washed 6x with PBS-T. Nuclear staining was performed with Hoechst 33342 (Thermo Fisher) 1 : 10,000 during the final wash with shaking for 5 min. One hundred microliters of PBS was added into each well and plates were stored at 4 °C until imaging on a confocal microscope (Zeiss 710).

Immunization of AG129 mice with vaccine candidates: DENV2 VLPs and Bin/J/DENV2-prME comparative study

Female AG129 mice (6–8 weeks old) were divided into ten groups of five mice each: immunization by ID or SC injections with Bin/J/DENV2-prME, Bin/J/DENV2-prME + QA (Desert King), DENV2 VLP (The Native Antigen), DENV2 VLP + QA and non-vaccinated control groups (saline only). Each mouse received 1 µg of Bin/J/DENV2-prME or 1 µg of DENV2 VLP, either with or without 3 µg of QA. All mice were immunized three times with 21 days between booster doses. Tail bleeds were taken on day 0, 20, 41 and 51 post first immunization. The serum fraction of each sample was recovered by leaving the blood samples to clot overnight at 4 °C, then centrifuging them at 10,000 × g for 10 min at 4 °C and stored at −20 °C until further analysis.

Immunization of AG129 mice with vaccine candidate: HD-MAP study

Female AG129 mice (6–8 weeks old) were divided into six groups of eight mice for immunization by either ID injections or HD-MAPS delivery with Bin/J/DENV2-prME or non-vaccinated control groups (saline). Each mouse received 1 µg of purified Bin/J/DENV2-prME. Mice (n = 16) immunized with Bin/J/DENV2-prME were split randomly into two groups (n = 8). The first group was challenged after a single vaccination, whereas the second group was given a booster dose 21 days later. Tail bleeds were taken on day 0 and 20 post primary immunization for the single-dose group and on day 41 for the two-dose groups. Sera were collected as stated above.

Virus challenge

Mice were challenged 10 days (comparative study) and 21 days (HD-MAP study) after the final vaccination. Then, 10⁵ pfu of the mouse-adapted DENV2 D220 strain were injected intraperitoneally into each mouse. Daily weight and tail bleeds were taken for 10 days post infection. Mice were monitored twice daily for morbidity and terminal bleed was collected 10 days post infection.

DENV-specific IgG ELISA

To assess for seroconversion to the vaccine candidates, ELISA plates (Nunc Maxisorb, Thermo Fisher) were coated with 80 ng/well of Bin/J/DENV2-prME in PBS overnight at 4 °C. Plates were blocked with blocking buffer (KPL, SeraCare) for 1 h at room temperature. The vaccinated mouse sera were initially diluted 1 : 100, then 5-fold down a 96-well plate in blocking buffer before adding 50 µL of diluted sera to the ELISA plate and incubated at 37 °C for an hour. Plates were washed four times with PBS-T and then probed with 50 µL/well of HRP-labelled goat anti-mouse (1 : 1000, Thermo Fisher). TMBW was then added.
added after washing the plates for six times with PBS-T and relative absorbance was measured at 450 nm on a plate reader.

**Plaque reduction neutralization tests**

Vero cells were seeded at 4 x 10^5 cells/well in a 96-well plate (Thermo Fisher) and incubated overnight at 37 °C/5% CO₂. Mouse sera obtained after final vaccination were heat inactivated at 56 °C for 30 min. Sera were diluted 1:25 then serially diluted 2-fold down a 96-well plate in serum-free OPTI-MEM. An equal volume of DENV2 ET00 virus stock was added at 75 pfu/well to the sera dilution. The virus–serum mixture was allowed to incubate for 1 h at 37 °C before adding 50 µL of it to the confluent Vero cells. Following a 1 h incubation at 37 °C, the medium was removed and the cells were overlayed with 100 µL of 1.5% carboxymethylcellulose in M199 media (Thermo Fisher) supplemented with 2% PBS. The plates were incubated for 3 days at 37 °C after which the overlay was removed and the cell monolayers washed twice with PBS. Cells were then fixed with 100 µL ice-cold 80% acetone in PBS for 20 min at −20 °C. Fixative was removed and plates were allowed to dry overnight, prior to immunofluorescence staining described below.

**Immunofluorescence staining**

Fixed PRNT or plaque assay plates were blocked with 150 µL/well of 0.1% BSA in PBS for 1 h at room temperature. After removing the blocking buffer, 50 µL/well of 1:1000 diluted rabbit anti-NS1 polyclonal antibody in blocking buffer was added and incubated at 37 °C for 1 h. Following four washes with PBS-T, 50 µL/well of 1:1000 diluted donkey anti-rabbit IR800 (Millennium) antibody was added and the plates incubated for a further 1 h at 37 °C. The plates were washed six times with PBS-T and allowed to dry completely before visualizing and imaging on the Odyssey Clx machine. Plaques were counted and virus titres were determined.

**Quantification of viremia by plaque assays**

Vero cells were seeded at 4 x 10^5 cells/well in a 96-well plate (Thermo Fisher) overnight at 37 °C. On a separate 96-well plate, sera obtained during daily bleeds post-infection were first diluted 1:10 then serially diluted twofold down the plate in OPTI-MEM media. Media were removed from cells, and 50 µL of serially diluted sera were added to the cells and allowed to incubate at 37 °C for 2 h. After incubation, the serially diluted sera were removed and the cells were overlaid with 1.5% carboxymethylcellulose as described for the PRNTs. Immunofluorescence staining was performed as stated above.

**NS1 quantitative capture ELISA**

NS1 capture ELISA was performed as described by Muller et al. Briefly, plates (Nunc Maxisorb) were coated with 50 µL of 5 µg/mL anti-NS1 monoclonal antibody in bicarbonate buffer overnight at 4 °C. Plates were incubated in blocking buffer (1% sucrose in 1x KPL in PBS-T) for 1 h at room temperature. Mouse sera obtained from the daily bleeds during the 10-day challenge were diluted 1:100 and 50 µL of the diluted sera was added to each well in duplicates. Plates were incubated for 1 h at 37 °C and then were washed 4x with PBS-T. Fifty microtitre plates of detection antibody (anti-NS1-HRP; Panbio) was added into each well and incubated for 1 h at 37 °C. Plates were then washed 6x with PBS-T before adding 50 µL/well of TMBW. Absorbance was read at 450 nm and quantified against a standard curve plotted using samples of known NS1 concentration.

**Statistical analysis**

All analyses were performed using GraphPad Prism version 7.0 (San Diego, CA, USA). One-way analysis of variance was performed for multiple comparison analysis with the α-level set at 0.05 with a Tukey’s post test.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

The authors declare that all data supporting the findings of this study are available within the paper and its Supplementary Information files.

**REFERENCES**

1. Bhatt, S. et al. The global distribution and burden of dengue. *Nature* **496**, 504–507 (2013).
2. Guzman, M. G. et al. Dengue: a continuing global threat. *Nat. Rev. Microbiol.* **8**, 57–516 (2010).
3. Wilder-Smith, A., Ooi, E.-E., Horstick, O. & Wills, B. Dengue. *Lancet* **393**, 350–363 (2019).
4. Islam, R. et al. Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past. *Virology* **30**, 326–343 (2015).
5. Yacoub, S. et al. Association of microvascular function and endothelial biomarkers with clinical outcome in dengue: an observational study. *J. Infect. Dis.* **214**, 697–706 (2016).
6. Martina, B. E., Kolar, O. & Osterhaus, A. D. Dengue virus pathogenesis: an integrated view. *Clin. Microbiol. Rev.* **22**, 564–581 (2009).
7. Wahala, W. M. & Silva, A. M. The human antibody response to dengue virus infection. *Virus* **3**, 2374–2395 (2011).
8. Muller, D. A. et al. NS1: defining protective versus pathologic immunity. *J. Clin. Invest.* **113**, 946–951 (2004).
9. Halsted, S. B. & O'Rourke, E. J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. *J. Exp. Med.* **146**, 201–217 (1977).
10. Capeding, M. R. et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet* **384**, 1358–1365 (2014).
11. Wider-Smith, A. & Massad, E. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. *Expert Rev. Vaccines* **15**, 437–441 (2016).
12. Hobson-Peters, J. et al. A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus. *Sci. Transl. Med.* **11**, eaax7888 (2019).
13. Vet, L. J. et al. Protective efficacy of a chimeric insect-specific flavivirus vaccine against West Nile virus. *Vaccines* **8**, 258–272 (2020).
14. Yan, K. et al. A yellow fever virus 17D infection and disease mouse model used to evaluate a chimeric Binjari-yellow fever virus vaccine. *Vaccines* **8**, 368–381 (2020).
15. Muller, D. A. et al. Efficient delivery of dengue virus subunit vaccines to the skin by microprojection arrays. *Vaccines* **7**, 189–202 (2019).
16. Muller, D. A. et al. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. *Sci. Rep.* **7**, 12644 (2017).
17. Muller, D. A. et al. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. *Sci. Rep.* **6**, 22094 (2016).
18. Forster, A. H. et al. Safety, tolerability, and immunogenicity of influenza vaccine with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. *PloS Med.* **17**, e1003024 (2020).
19. Fernando, G. J. et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. *PloS ONE* **5**, e10266 (2010).
20. Depelsenaire, A. C. I. et al. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. *J. Invest. Dermatol.* **134**, 2361–2370 (2014).
21. Ng, H.-I. et al. Microprojection arrays applied to skin generate mechanical stress, induce an inflammatory transcripome and cell death, and improve vaccine-induced immune responses. *npj Vaccines* **4**, 41 (2019).
22. Pierson, T. C. & Diamond, M. S. Degrees of maturity: the complex structure and biology of flaviviruses. *Curr. Opin. Virol.* **2**, 168–175 (2012).
23. Metz, S. W. et al. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. *Virology* **15**, 60–70 (2018).
24. Tassaneenithip, B. et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. *J. Exp. Med.* **197**, 823–829 (2003).
25. Thomas, S. J. & Endy, T. P. Current issues in dengue vaccination. *Curr. Opin. Infect. Dis.* **26**, 429–434 (2013).
26. Osorio, J. E., Partidos, C. D., Wallace, D. & Stinchcomb, D. T. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. *Vaccine* **33**, 7112–7120 (2015).
27. Collins, M. H. & Metz, S. W. Progress and works in progress: update on flavivirus vaccine development. *Clin. Ther.* **39**, 1519–1536 (2017).
28. Durbin, A. P. et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naïve adults: a randomized, double-blind clinical trial. *J. Infect. Dis.* **207**, 957–965 (2013).
29. Whitehead, S. S. et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3’ untranslated region is highly attenuated and immunogenic in monkeys. *J. Virol.* **77**, 1653–1657 (2003).

30. Osorio, J. E., Huang, C. Y. H., Kinney, R. M. & Stinchcomb, D. T. Development of DENvax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. *Vaccine* **29**, 7251–7260 (2011).

31. Moyle, P. M. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. *Biotechnol. Adv.* **35**, 375–389 (2017).

32. Hazlewood, J. E. et al. A Zika vaccine generated using the chimeric insect-specific Binjari virus platform protects against fetal brain infection in pregnant mice. *Vaccines* **8**, 496–508 (2020).

33. Zehn, D., Jarrahian, C. & Wales, A. Intradermal delivery for vaccine dose sparing: overview of current issues. *Vaccine* **31**, 3392–3395 (2013).

34. Andreata-Santos, R. et al. Transcutaneous administration of dengue vaccines. *Viruses* **12**, 514–530 (2020).

35. Turvey, M. E. et al. Microneedle-based intradermal delivery of stabilized dengue virus. *Bioeng. Transl. Med.* **4**, e10127 (2019).

36. Kim, E. et al. Preventative vaccines for Zika virus outbreak: preliminary evaluation. *EBioMedicine* **13**, 315–320 (2016).

37. Warrilow, D. et al. A new species of mesonivirus from the Northern Territory, Australia. *PLoS ONE* **9**, e91103 (2014).

38. Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. *Nat. Immunol.* **16**, 170–177 (2015).

39. Wong, Y. H. et al. Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513. *Sci. Rep.* **8**, 8449 (2018).

40. O’Brien, C. A. et al. Viral RNA intermediates as targets for detection and discovery of novel and emerging mosquito-borne viruses. *PLoS Negl. Trop. Dis.* **9**, e0003629 (2015).

41. Clark, D. C. et al. In situ reactions of monoclonal antibodies with a viable mutant of Murray Valley encephalitis virus reveal an absence of dimeric NS1 protein. *J. Gen. Virol.* **88**, 1175–1183 (2007).

42. Harrison, J. J. et al. Antigenic characterization of new lineage II insect-specific flaviviruses in Australian mosquitoes and identification of host restriction factors. *mSphere* **5**, e00095–00020 (2020).

ACKNOWLEDGEMENTS

This work was supported by National Health and Medical Research Development grants from the Australian Government, APP1139754 and APP1178896. J.J.Y.C. and L.J.V. are recipients of University of Queensland Research Training Scholarship. C.A.P.S. is a recipient of Australian Government Research Training Scholarship (earmarked). We thank the animal house staff at the AIBN animal facility for providing technical assistance. We also thank Professor Eva Harris for providing the D220 dengue virus type 2. HD-MAPs were provided by Vaxxas Pty Ltd. This work was performed in part at the Queensland Node of the Australian National Fabrication Facility, a company established under the National Collaborative Research Infrastructure Strategy to provide nano- and micro-fabrication for Australia’s researchers.

AUTHOR CONTRIBUTIONS

Project oversight: D.A.M., J.H.-P., R.A.H., and P.R.Y. Experimental design: J.J.Y.C. and D.A.M. Experiments: J.J.Y.C., L.J.V., D.A.M., C.A.P.S., C.L.D.M. and J.J.H. HD-MAP coating optimization: A.C.I.D. Writing, original draft preparation: J.J.Y.C. and D.A.M. Writing, review and editing: all authors.

COMPETING INTERESTS

D.A.M., G.I.P.F. and P.R.Y. are consultants, while A.C.I.D. is an employee of the HD-MAP development company Vaxxas Pty Ltd. Data included in this publication are based on a patent (WO/2018/176075) on which L.J.V., J.J.H., D.W., R.A.H. and J.H.-P. are inventors. The remaining authors declare no conflicts.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41541-021-00328-1.

Correspondence and requests for materials should be addressed to J.H.-P. or D.A.M.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021